Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine (E+G) versus gemcitabine (G) alone.
2010 ◽
Vol 28
(15_suppl)
◽
pp. 4079-4079
Keyword(s):
2021 ◽
Vol 39
(15_suppl)
◽
pp. 4119-4119
2010 ◽
Vol 28
(10)
◽
pp. 1645-1651
◽
2012 ◽
Vol 48
(10)
◽
pp. 1434-1442
◽
Keyword(s):
2007 ◽
Vol 25
(15)
◽
pp. 1960-1966
◽
2010 ◽
Vol 28
(22)
◽
pp. 3617-3622
◽
2007 ◽
Vol 25
(16)
◽
pp. 2212-2217
◽
2004 ◽
Vol 22
(8)
◽
pp. 1430-1438
◽
2005 ◽
Vol 23
(16_suppl)
◽
pp. 4105-4105
◽
Keyword(s):
2014 ◽
Vol 32
(23)
◽
pp. 2423-2429
◽